- Home
- PSNL vs AKBA Comparison
PSNL vs AKBA Comparison
Compare PSNL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | AKBA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 729.1M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PSNL | AKBA |
|---|---|---|
| Price | $9.19 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $10.71 | $6.25 |
| AVG Volume (30 Days) | 1.4M | ★ 4.1M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $69,103,000.00 | ★ $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | $20.33 | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $2.83 | $1.45 |
| 52 Week High | $11.40 | $4.08 |
Technical Indicators
Market Signals| Indicator | PSNL | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 43.78 |
| Support Level | $9.34 | $1.45 |
| Resistance Level | $9.85 | $1.61 |
| Average True Range (ATR) | 0.78 | 0.08 |
| MACD | -0.12 | 0.05 |
| Stochastic Oscillator | 31.13 | 88.24 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.